In humans with type 2 diabetes, exogenous insulin treatment has been linked to an increased risk of developing breast cancer [25–27] and poorer breast cancer outcomes [28–30], although the impact of exogenous insulin on tumor progression is debatable: recent meta-analyses failed to detect an impact of insulin treatment on breast cancer incidence [31–33]. This evidence concerns the gene INS and breast cancer.